Last but not least, SGLT2 inhibitors and intravenous iron supplementation both have, as a single treatment, a positive impact on HF; however, the effects of their combined use have not yet been tested in any clinical trial. The gene discussed is SLC5A2; the disease is hydrops fetalis.